Life Sciences

GSK warned about misleading TV ad

Pharma Compliance Alert, March 11, 2009

A direct-to-consumer television ad misbrands GlaxoSmithKline’s prostate drug Avodart, according to an FDA warning letter.

The 60-second ad presents misleading comparative claims and overstates the efficacy of Avodart. Specifically, the ad claims Avodart is the only medication that shirks the prostate. Merck’s Proscar also reduces the size of the prostate and has a similar indication. Visual effects in the ad also exaggerate Avodart’s effectiveness, according to the FDA.

    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

  • Needlestick Prevention Training Video

    Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...

Most Popular